Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review
- 24 January 2020
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 43 (5) , 395-408
Abstract
Hyperkeratotic skin adverse events are a group of toxic effects, characterized by the disruption of epidermal homeostasis and interaction with keratinocyte proliferation/differentiation or keratinocyte survival, and frequently reported with systemic anticancer treatments. These types of reactions include hand–foot skin reaction or palmoplantar keratoderma, induced psoriasis, keratosis pilaris-like or pityriasis rubra pilaris-like rashes, Grover’s disease, and contact hyperkeratosis. Cutaneous squamoproliferative lesions are also described because of the presence of abnormal keratinocyte proliferation. They are usually observed with tyrosine kinase inhibitors but have also been described in association with cytotoxic chemotherapeutic agents. Their pathogenesis is related mainly to the disruption of epidermal homeostasis and interaction with keratinocyte proliferation/differentiation or keratinocyte survival caused by anticancer treatment. Early recognition and adequate management are critical to prevent exacerbation of the lesions, to limit treatment interruption, and to minimize impairment of quality of life. This review summarizes the current knowledge concerning the presentation, pathogenesis, and management of secondary hyperkeratotic reactions to anticancer therapies. It also includes hyperkeratotic reactions that have been more recently described with newly approved targeted therapies or immune checkpoint inhibitors, such as keratosis pilaris-like exanthema with second-generation BCR-ABL inhibitors, lamellar ichthyosis-like lesions with ponatinib, pityriasis rubra pilaris with the newly approved selective phosphoinositide 3 kinase inhibitor idelalisib, or psoriasis with anti-programmed death-1 and programmed death ligand-1.Keywords
This publication has 96 references indexed in Scilit:
- Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic OligodendrogliomaCase Reports in Rheumatology, 2012
- Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?Dermatology, 2012
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsJournal of Clinical Oncology, 2012
- HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot SyndromeThe Oncologist, 2011
- Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?Targeted Oncology, 2009
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBritish Journal of Dermatology, 2009
- Array of cutaneous adverse effects associated with sorafenibJournal of the American Academy of Dermatology, 2009
- Dermatologic symptoms associated with the multikinase inhibitor sorafenibJournal of the American Academy of Dermatology, 2009
- Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatmentJournal of the American Academy of Dermatology, 2006
- Inflammation of actinic keratoses from systemic chemotherapyJournal of the American Academy of Dermatology, 1987